$VANI

Williams Gregg purchased $1,000K of VANI (indirect holdings)

Williams Gregg purchased 793,650 indirectly-held shares of Vivani Medical, Inc. (VANI) at $1.26 ($1.00M total) on 2026-07-15.

Original reporting
SEC EDGAR · Williams Gregg
Published Jul 16, 2026, 1:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 16, 2026, 1:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$VANI
Bullish
medium confidence
Mentioned
$VANI
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VANIBullishLow
01

Why it matters

A director and 10% owner purchased 793,650 shares at $1.26 for about $1.0M, with holdings after the transaction reported as 36,912,736 shares.

02

Market read

Traders may monitor for follow-on insider activity, but the filing does not include operational or financial updates.

03

What to watch

No 10b5-1 plan is stated, but the filing does not disclose the underlying reason for the indirect purchase or whether other insiders are acting similarly.

Relevance 6/10Novelty 6/10Timing: new Form 4 filed 2026-07-16, covering a 2026-07-15 purchase

Background

This is an SEC Form 4 insider transaction for Vivani Medical, Inc. (VANI).

Company-level read

Ticker impact

$VANIBullishMedium confidence
Context

Vivani Medical director and 10% owner Williams Gregg bought 793,650 shares at $1.26 on 2026-07-15 via an indirect holding form.

Expected impact

Likely limited near-term impact; may modestly support sentiment if traders treat insider buying as a signal.

Evidence & confidence

Form 4 confirms a large dollar-value open-market purchase (~$1.0M) and no 10b5-1 plan, but insider buys alone rarely drive sustained repricing without additional disclosures.

Market effects

No sector-level read-across; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The purchase may reflect diversification, tax planning, or pre-existing arrangements rather than a new bullish thesis, especially with indirect holdings.

Key entities

  • Vivani Medical, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Williams Gregg

    Director and 10% owner who purchased shares via an indirect holding form.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VANIMed

Vivani Medical, Inc. (VANI): Results of Operations and Financial Condition

Vivani Medical, Inc. (VANI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight mana

$VANIMed

Vivani Flat on Hookup with Novo

Vivani Medical (NASDAQ: VANI) said it signed an agreement with Novo Nordisk to let Novo evaluate Vivani’s NPM-139 semaglutide implant using Vivani’s NanoPortal platform for chronic weight management. Vivani noted no exclusivity. It plans to start a Phase 1 first-in-human study mid-2026, using Wegovy as comparator, to support a Phase 2 dose-ranging study.

$VANIMedAI 8/10

Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

Vivani Medical (Nasdaq: VANI) said its subsidiary Cortigent will merge into ClearOne (Nasdaq: CLRO), with Cortigent becoming a wholly owned ClearOne unit. ClearOne plans a concurrent $10–15M financing via an S-1. Vivani will receive 12.5M ClearOne shares for 59.4%–67.5% ownership; ClearOne will rename to Cortigent Holdings (CRGT), expected to close Q3 2026.

$VANIMedAI 8/10

Vivani Medical, Inc.: Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

Vivani Medical (Nasdaq: VANI) said its subsidiary Cortigent will merge into ClearOne (Nasdaq: CLRO) via a definitive agreement, making Cortigent a wholly owned ClearOne unit. ClearOne plans a concurrent $10m–$15m financing. Vivani will receive 12.5m ClearOne shares and own 59.4%–67.5%; the combined company will trade as CRGT, expected to close Q3 2026.